Current News
September 05, 2014
Directors Nominated By Dissident Shareholder Elected At Annual General Meeting
September 04, 2014
Med BioGene Announces Receipt of Proxies for Upcoming Annual and Special Meeting
August 06, 2014
Med BioGene Announces Director Nominations and Postponement of Annual and Special Meeting
March 07, 2014
Med BioGene Announces Publication of Data Demonstrating Independent Validation of GeneFx® Lung
January 09, 2014
Med BioGene Announces Dismissal of Litigation With Signal Genetics LLC and Respira Health LLC
| APPOINTMENT OF NEW DIRECTOR
Vancouver, B.C., March2, 2015 – Med BioGene Inc. (“MBI” or the “Company”) (TSXV: MBI) wishes to announcethat Ms. Shumsheer Sidhu, B.Sc., has accepted the invitation of the Company’s Directors to join the Board. Ms. Sidhu is a graduate of the University of British Columbia, and is both a CMA and CPA. Since graduation she has worked in the healthcare sector in a financial management capacity. She is currently the Finance Manager at NeuroDevNet, the first Trans-Canada initiative dedicated to studying children’s brain development. Ms. Sidhu has been a shareholder of the Company since 2013 and has a substantial interest in the long term growth of this Company. This appointment is in accordance with the previously stated policy of the Company to diversify the management and Board by involving representatives of the shareholders at the Board level, and to become more responsive to the concerns of the shareholders at large. Ms. Sidhu shares this objective and will become a member of the Company’s Audit Committee under the Chairmanship of David Diebolt, CA. In accordance with the policy outlined before the last Annual General Meeting, Ms. Sidhu has agreed to forego Director’s fees until the Company’s GeneFX Lung™ has been commercialized and positive cash flow has been achieved. The Company hopes to announce commercialization in Q4 2015 and is working with its development partner Helomics to make this a reality. About Med BioGene Inc. MBI is a life science company based in Vancouver, British Columbia that is currently focused on managing the license and rights to GeneFX Lung™,a prognostic genomic based test procedure. MBI’s common shares are listed for trading on the Exchange. For more information, please visit www.medbiogene.com For further information contact: Iain Weir-Jones, Chief Executive Officer and Chairman of the Board of Directors
|
|
© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer